Bimatoprost implant improves long term results in glaucoma treatment

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-07-11 06:41 GMT | Update On 2020-07-11 06:41 GMT

USA: The bimatoprost implant has the potential to improve adherence and reduce the treatment burden in glaucoma, according to a recent study published in the journal Ophthalmology. Results from the phase III study revealed that both 10-µg and 15-µg implants are efficient in maintaining lowered intraocular pressure (IOP) for up to 12 months after the final implant placement.

Open-angle glaucoma (OAG) is a vision-threatening, chronic, irreversible disease that requires IOP lowering treatment for slowing or preventing the disease progression. As the disease advances, the economic costs of glaucoma increases and quality of life decreases due to which early management and adherence to treatment are important.

Felipe A. Medeiros, Department of Ophthalmology, Duke University, Durham, North Carolina, and colleagues conducted the study to evaluate the IOP lowering efficacy and safety of 10- and 15-μg bimatoprost implant in subjects with OAG and ocular hypertension (OHT) after initial and repeated administrations.

The randomized phase 3 clinical trial included adults with OAG or OHT in each eye, open iridocorneal angle inferiorly in the study eye by clinical gonioscopy, and study eye baseline IOP (H0; 8 am±1 h) of 22–32 mmHg after washout. Study eyes received bimatoprost implant 10 μg (n=198) or 15 μg (n=198) on Day 1 with readministration at Weeks 16 and 32, or twice-daily topical timolol maleate 0.5% (n=198). IOP was measured at Hours 0 and 2 at each visit.

Primary endpoints were IOP and change from baseline IOP through Week 12.

Key findings of the study include:

Over the study period, the proportion of TAVR performed using CS increased from 33% to 64%, and CS was used in a median of 0% and 91% of cases in the lowest and highest quartiles of hospital CS use, respectively.
On the basis of instrumental variable analysis, CS was associated with decreases in in-hospital mortality (adjusted risk difference: 0.2%) and 30-day mortality (adjusted risk difference: 0.5%), shorter length of hospital stay (adjusted difference: 0.8 days), and more frequent discharge to home (adjusted risk difference: 2.8%) compared with GA.
The magnitude of benefit for most endpoints was less than in a traditional propensity score–based approach.

"Ongoing studies are evaluating other administration regimens to reduce the potential for CECD loss. The bimatoprost implant has the potential to improve adherence and reduce treatment burden in glaucoma," concluded the authors.

The study, "Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)," is published in the journal Ophthalmology.

DOI: https://doi.org/10.1016/j.ophtha.2020.06.018

Article Source : Ophthalmology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Bimatoprost implant improves long term results in glaucoma treatment

Similar News

Could we use eye drops instead of reading glasses as we age?

Low Hb Levels may Increase Risk of Diabetic Retinopathy in Adults with Type 2 Diabetes: Study

Cataract surgery on both eyes can be carried out safely and effectively in one go, reveals study

The Hidden Metabolic Story Behind Vision-Saving Treatment

Antidepressant Use Linked to Lower Risk of Age-Related Macular Degeneration: Study Shows

Roche receives EU CE mark for Contivue for neovascular age-related macular degeneration

Anti-VEGF Eye Injections tied to minor Increase in Stroke Risk, suggests research

GLP-1 RAs closely associated with increased risk of developing incident diabetic retinopathy: JAMA